Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

AB-1002 is an investigational gene therapy for the treatment of adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III heart failure symptoms GenePHIT is a clinical ...

Gene therapy represents a paradigm shift in modern medicine, offering unprecedented opportunities to combat diseases at their ...

For the last 10 years, the only effective treatment for hypophosphatasia (HPP) has been an enzyme replacement therapy that ...

AB-1002 is an investigational gene therapy for the treatment of adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III heart failure symptoms GenePHIT is a clinical ...

"The potential of gene therapy to address the intracellular abnormalities that characterize heart failure is immense, and we are excited to have achieved this critical milestone for the GenePHIT ...

Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...

This FDA-approved therapy is based ... a virus engineered to not cause disease but rather to deliver a gene capable of producing the missing TNAP enzyme and reversing the malformation of bones ...

Researchers developed an epigenetic editing approach to silence the PCSK9 gene, achieving long-term cholesterol reduction ...

Now scientists have discovered a dormant gene that could be reactivated to regenerate heart tissue, preventing the progression to heart failure. After a heart attack, scar tissue often forms to ...

They found that the enzyme may prevent a stiff heart through activating the gene ... of heart failure," Yoshida summarized. "HFpEF is a growing global concern due to limited drug therapy options.